Evaluation of Bacterial Polysaccharide Immune Globulin for the Treatment or Prevention of Haemophilus influenzae Type b and Pneumococcal Disease

George R. Siber, Claudette Thompson, G. Raymond Reid, Janné Almeido-Hill, Bonnie Zacher, Mark Wolff, Mathuram Santosham

Research output: Contribution to journalArticle

Abstract

A human hyperimmune globulin termed bacterial polysaccharide immune globulin (BPIG) has been prepared from plasma donors immunized with Haemophilus influenzae type b (Hib), pneumococcal, and meningococcal vaccines. At a dose of 0.5 ml/kg, BPIG increased levels of antibody to Hib by >0.15 µg/ml within 4-6 h and by 2-4 µg/ml at 72 h. Thereafter, antibody declined, with a mean half-life of 27 days. BPIG treatment of Apache infants did not impair their active antibody responses to concurrently administered diphtheria-tetanus-pertussis or Hib oligo-saccharide-diptheria CRM197conjugate vaccines. In high-risk Apache infants, BPIG given at 2, 6, and 10 months of age provided significant protection from invasive Hib infection during infancy. Thus, BPIG may have utility in the prevention of Hib infections in high-risk patients who cannot be immunized adequately with Hib conjugate vaccines.

Original languageEnglish (US)
Pages (from-to)S129
JournalJournal of Infectious Diseases
Volume165
DOIs
StatePublished - 1992

Fingerprint

Haemophilus influenzae type b
Haemophilus Vaccines
Therapeutics
Meningococcal Vaccines
Conjugate Vaccines
Pneumococcal Vaccines
Diphtheria
Antibodies
Whooping Cough
Globulins
Tetanus
Infection
Antibody Formation
Half-Life
bacterial polysaccharide immune globulin
Vaccines
Tissue Donors

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy
  • Immunology
  • Public Health, Environmental and Occupational Health

Cite this

Evaluation of Bacterial Polysaccharide Immune Globulin for the Treatment or Prevention of Haemophilus influenzae Type b and Pneumococcal Disease. / Siber, George R.; Thompson, Claudette; Raymond Reid, G.; Almeido-Hill, Janné; Zacher, Bonnie; Wolff, Mark; Santosham, Mathuram.

In: Journal of Infectious Diseases, Vol. 165, 1992, p. S129.

Research output: Contribution to journalArticle

Siber, George R. ; Thompson, Claudette ; Raymond Reid, G. ; Almeido-Hill, Janné ; Zacher, Bonnie ; Wolff, Mark ; Santosham, Mathuram. / Evaluation of Bacterial Polysaccharide Immune Globulin for the Treatment or Prevention of Haemophilus influenzae Type b and Pneumococcal Disease. In: Journal of Infectious Diseases. 1992 ; Vol. 165. pp. S129.
@article{3f29b67426e1451e8c1dd9d77f6a5657,
title = "Evaluation of Bacterial Polysaccharide Immune Globulin for the Treatment or Prevention of Haemophilus influenzae Type b and Pneumococcal Disease",
abstract = "A human hyperimmune globulin termed bacterial polysaccharide immune globulin (BPIG) has been prepared from plasma donors immunized with Haemophilus influenzae type b (Hib), pneumococcal, and meningococcal vaccines. At a dose of 0.5 ml/kg, BPIG increased levels of antibody to Hib by >0.15 µg/ml within 4-6 h and by 2-4 µg/ml at 72 h. Thereafter, antibody declined, with a mean half-life of 27 days. BPIG treatment of Apache infants did not impair their active antibody responses to concurrently administered diphtheria-tetanus-pertussis or Hib oligo-saccharide-diptheria CRM197conjugate vaccines. In high-risk Apache infants, BPIG given at 2, 6, and 10 months of age provided significant protection from invasive Hib infection during infancy. Thus, BPIG may have utility in the prevention of Hib infections in high-risk patients who cannot be immunized adequately with Hib conjugate vaccines.",
author = "Siber, {George R.} and Claudette Thompson and {Raymond Reid}, G. and Jann{\'e} Almeido-Hill and Bonnie Zacher and Mark Wolff and Mathuram Santosham",
year = "1992",
doi = "10.1093/infdis/165-Supplement_1-S129",
language = "English (US)",
volume = "165",
pages = "S129",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Evaluation of Bacterial Polysaccharide Immune Globulin for the Treatment or Prevention of Haemophilus influenzae Type b and Pneumococcal Disease

AU - Siber, George R.

AU - Thompson, Claudette

AU - Raymond Reid, G.

AU - Almeido-Hill, Janné

AU - Zacher, Bonnie

AU - Wolff, Mark

AU - Santosham, Mathuram

PY - 1992

Y1 - 1992

N2 - A human hyperimmune globulin termed bacterial polysaccharide immune globulin (BPIG) has been prepared from plasma donors immunized with Haemophilus influenzae type b (Hib), pneumococcal, and meningococcal vaccines. At a dose of 0.5 ml/kg, BPIG increased levels of antibody to Hib by >0.15 µg/ml within 4-6 h and by 2-4 µg/ml at 72 h. Thereafter, antibody declined, with a mean half-life of 27 days. BPIG treatment of Apache infants did not impair their active antibody responses to concurrently administered diphtheria-tetanus-pertussis or Hib oligo-saccharide-diptheria CRM197conjugate vaccines. In high-risk Apache infants, BPIG given at 2, 6, and 10 months of age provided significant protection from invasive Hib infection during infancy. Thus, BPIG may have utility in the prevention of Hib infections in high-risk patients who cannot be immunized adequately with Hib conjugate vaccines.

AB - A human hyperimmune globulin termed bacterial polysaccharide immune globulin (BPIG) has been prepared from plasma donors immunized with Haemophilus influenzae type b (Hib), pneumococcal, and meningococcal vaccines. At a dose of 0.5 ml/kg, BPIG increased levels of antibody to Hib by >0.15 µg/ml within 4-6 h and by 2-4 µg/ml at 72 h. Thereafter, antibody declined, with a mean half-life of 27 days. BPIG treatment of Apache infants did not impair their active antibody responses to concurrently administered diphtheria-tetanus-pertussis or Hib oligo-saccharide-diptheria CRM197conjugate vaccines. In high-risk Apache infants, BPIG given at 2, 6, and 10 months of age provided significant protection from invasive Hib infection during infancy. Thus, BPIG may have utility in the prevention of Hib infections in high-risk patients who cannot be immunized adequately with Hib conjugate vaccines.

UR - http://www.scopus.com/inward/record.url?scp=0026632876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026632876&partnerID=8YFLogxK

U2 - 10.1093/infdis/165-Supplement_1-S129

DO - 10.1093/infdis/165-Supplement_1-S129

M3 - Article

VL - 165

SP - S129

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

ER -